The purpose of this study was to evaluate the toxicity and potential efficacy of administering the THERA-TOPE ® STn-KLH cancer vaccine to ovarian and breast cancer patients after an autologous stem cell transplant. Forty patients (11 high-risk stage II/III breast cancer, 22 stage IV breast cancer, and seven stage III/IV ovarian cancer patients) were treated with highdose chemotherapy followed by autologous/syngeneic stem cell rescue and vaccination with THERATOPE STn-KLH (Sialyl-Tn-KLH with Detox-B Stable Emulsion). Each patient was scheduled to receive a total of five vaccinations beginning on days 30-151 after stem cell infusion. The vaccine was well tolerated. Induration and erythema at the site of injection were the most common side-effects. When one compares the outcome of patients vaccinated with 66 breast and ovarian cancer patients who were not, following risk-adjustment analysis, vaccinated patients appeared more likely to survive (P = 0.07) and less likely to relapse (P = 0.10). Vaccinated patients with the greatest specific lytic activity against STn + OVCAR tumor cells relative to nonspecific killing of Daudi cells tended to remain in remission longer than patients who displayed less specific immune activity (P = 0.057). We conclude that the THERATOPE STn-KLH cancer vaccine is well tolerated in breast and ovarian cancer patients after autologous transplant and, while not statistically significant, the trends in data support the concept that THERATOPE vaccine may decrease the risk for relapse and death and thus warrants further study. Bone Marrow Transplantation (2000) 25, 1233-1241.
The success of high-dose chemotherapy followed by autologous stem cell rescue for patients with solid tumors, such as breast and ovarian cancer, is limited by high relapse rates. [1] [2] [3] [4] Attempts to improve outcome by further dose intensification of a single conditioning regimen have led to an increase in transplant-related morbidity and mortality without a reduction in relapse rates. Relapses may result from the infusion of contaminating tumor cells in the stem cell product 5 and from the incomplete eradication of endogenous malignant cells by the treatment regimen.
Current research in transplantation has focused on trying, after a single autologous transplant, to augment the immune system to recognize tumor-specific antigens as a means to delay or prevent relapse. One of the ways to deliver such active-specific immunotherapy is through the administration of a cancer-specific vaccine. Numerous animal and human studies have shown that cancer vaccines stimulate not only specific humoral but also cell-mediated immune responses. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] STn is a disaccharide antigen that is associated with MUC1 mucin core peptide that is present on a number of cancers. 16, 17 Several studies of ovarian carcinoma have shown that serum STn levels are associated with outcome. 18 The percentage of immunoreactive carcinoma positive for STn has been reported to vary from 31 to 100% in ovarian cancer [19] [20] [21] and from 25 to 75% in breast cancer. 22 Over 450 patients with metastatic adenocarcinoma have been treated to date in clinical trials in a nontransplant setting with THERATOPE ® STn-KLH cancer vaccine (Refs 11-15, 23-26 and unpublished data). In these studies, patients who produced the highest antibody titers against mucin expressed STn epitopes following vaccination survived longer than those patients who produced the lowest titers. 13 Although cellular immune responses to STn were not followed in these nontransplant studies, the efficacy of similar carbohydrate cancer vaccines to carbohydrate in animal models does correlate with the magnitude of the delayed-type hypersensitivity reaction to the Tn or Thomsen-Friedenreich carbohydrate antigen. 27 In addition, T cell recognition of tumor-associated Tn antigen displays a high degree of carbohydrate specificity. 28 In general, immunotherapy may be most effective in controlling tumor when it is given to patients with a low tumor burden. 23, 29 After high-dose chemotherapy followed by autologous stem cell infusion, the majority of patients should have a low tumor burden. 3 Consequently, in the present study, breast cancer and ovarian cancer patients who had undergone high-dose chemotherapy followed by autologous stem cell rescue were treated with THERA-TOPE STn-KLH cancer vaccine. Although it has been reported by other groups that transplant patients are especially immunosuppressed in their ability to develop humoral and cellular immune responses, 30 it has been previously published by our group that autologous transplant patients vaccinated with THERATOPE STn-KLH do mount strong cellular and humoral immune response against this cancer vaccine. 31 The majority of patients treated developed increasing anti-STn antibody titers with a sustained peak reached following the fourth or fifth vaccination. Sixty-three percent of the patients who received at least three immunizations demonstrated specific T cell proliferation to STn antigen, with 42% of the patients able to mount a TH1 response. In addition, following immunization, there was an increase in the expression of lytic activity against STn bearing tumor targets. 31 In spite of all this laboratory data, to date, most cancer vaccines have yet to demonstrate convincing evidence of clinical response. In this paper, we report the clinical outcome of 40 ovarian and breast cancer patients, who, following an autologous stem cell transplant were treated with THERATOPE STn-KLH cancer vaccine.
Patients and methods
Between 1 September 1995 and 18 November 1997, 40 patients with ovarian or breast cancer who had previously been treated with high-dose chemotherapy followed by either autologous or syngeneic peripheral blood stem cell (PBSC) rescue were vaccinated with THERATOPE STn-KLH. For patient characteristics, see Table 1 . All the patients with stage II breast cancer at transplant had у10 axillary lymph nodes at diagnosis, median 11.5 (range . One patient with stage IIIA breast cancer had previous neoadjuvant therapy before mastectomy. All patients received conventional chemotherapy prior to high-dose therapy. Basic supportive care measures, stem cell collection and infusion, and high-dose therapy with busulfan, melphalan and thiotepa (BUMELTT) have been previously described. 2 Patients were eligible for vaccination if they had a performance status after transplant of у70% Karnofsky score and had recovered from acute transplant toxicities with an absolute neutrophil count Ͼ1.5 × 10 9 /l and platelet count (untransfused) Ͼ20 × 10 9 /l. Other eligibility criteria were: total bilirubin or SGOT Ͻ2 × upper limit of normal (ULN), alkaline phosphatase Ͻ3 × ULN and creatinine р2.0 mg/dl. Patients could not have received other immunotherapy such as monoclonal antibodies or IL-2 within 6 weeks prior to beginning vaccination. Three patients were treated with IL-2 incubated PBSC and sequential IL-2 therapy more than 6 weeks prior to vaccination. Patients could not be receiving steroid therapy and could have no evidence of an active autoimmune disease. Patients who were allergic to shellfish or had a history of anaphylactic reaction to any drugs were also excluded from treatment. Finally, patients with a history of splenectomy were also not vaccinated.
Each patient received all immunizations at the Fred Hutchinson Cancer Research Center (FHCRC). Signed consent was obtained from all patients treated on the protocol that had been previously approved by the FHCRC Institutional Review Board under an Investigational New Drug License from the US Food and Drug Administration. If a patient relapsed while on study, she could continue to receive subsequent vaccinations if she and her oncologist agreed to her receiving no chemotherapy. Concomitant hormonal, surgery and radiation therapies were allowed. Eighteen patients received concomitant hormonal therapy and the vaccine, and seven patients received concomitant radiation therapy and vaccination.
Because there are a number of different immunotherapy and chemotherapy agents available to study in combination with an autologous transplant, a control group of nonvaccinated patients was identified for comparing their outcome with vaccinated patients. This comparison was undertaken to help us determine whether further studies with the THERATOPE STn-KLH cancer vaccine were warranted.
All patients in the control group initially received conventional therapy and were then treated with high-dose chemotherapy followed by autologous/syngeneic PBSC rescue during the same period of time as the vaccinated patients. All nonvaccinated patients also clinically met the eligibility criteria for the vaccine study, but were not vaccinated at their request or were not directly referred by their transplant oncologist for the study. For patient characteristics, see Table 1 . For patients with stage II breast cancer at transplant, three out of 18 (16.7%) had less than 10 axillary lymph nodes involved at diagnosis. (The median number of lymph nodes involved was 12, range 7-29.) Eight out of 21 (38%) of patients with stage III noninflammatory breast cancer had neoadjuvant therapy before mastectomy. Tumor cells from the vaccinated or nonvaccinated patients were not immunostained for the expression of STn.
Vaccine THERATOPE STn-KLH cancer vaccine (Biomira) with adjuvant Detox B SE (Detox B) (Ribi Immunochem Research, Hamilton, MT, USA) has previously been described. 15, 24, 25 The emulsified vaccine was injected subcutaneously (s.c.) at a dose of 100 g of vaccine in a 0.3 ml volume in each of two sites in upper arms, thighs or abdomen. Patients were scheduled to receive a total of five immunizations in the first year post transplant. The first immunization was administered on days 30 to 151 post stem cell infusion, median 127.5 days, when patients met the eligibility requirements for vaccination. The second immunization was given 2 weeks from the first, and the subsequent three immunizations were given at 2-3-month intervals. Ten out of 26 (38.5%) patients received their last vaccinations one year post transplant. Twenty-six out of 40 patients received all five vaccinations. Patients were monitored for the development of toxicities including anaphylactoid reaction, flu-like symptoms and local reactions such as pain, erythema, induration, granuloma formation or ulceration. Toxicities were graded by severity according to the WHO Toxicity Guidelines. cervical, supraclavicular and mediastinum (n = 3), lymph node/lung/liver (n = 1), supraclavicular lymph node (n = 1); control: liver (n = 2), chest wall (n = 1); liver/cervical/lymph node (n = 1), supraclavicular lymph node (n = 4)) 5 (15.2) 8 (13.1) bone alone 9 (27.3) 4 (6.6) both bone and viscera (vaccine: lung (n = 2), liver/lung (n = 3), chest wall (n = 1), and liver (n = 2); control: liver (n = 1), chest wall/liver (n = 1), lung/mediastinum (n = 1), cervical/supraclavicular lymph node (n = 2)) 8 (24. C = cytoxan; E = etoposide; P = cisplatin; BUMELTT = busulfan, melphalan and thiotepa.
Definitions
The duration of response was calculated from the day of PBSC infusion (day 0). All patients were restaged at sites of prior disease at days 60-85 post transplant and yearly after high-dose chemotherapy.
Patients with responsive stage IV breast cancer had disease that responded upon radiographic assessment by complete response (CR) or partial response (PR) (у50%) to the first therapy given for metastatic disease. All other patients with metastatic breast cancer were considered to have refractory disease. Patients with ovarian cancer were considered to have platinum-sensitive disease if their disease responded to initial therapy with platinum or had relapsed after 6 months from initial therapy with a platinum-containing regimen. Patients were considered to have platinum refractory ovarian cancer if their disease progressed on platinum-containing therapy or relapsed within 6 months of completing platinum-containing therapy.
Patients were followed for initial response to autologous/syngeneic transplant and for progression of disease. Response criteria were scored accordingly: (1) CR: complete disappearance of all clinically measurable disease by physical examination and radiographic evaluation for a minimum of 30 days; (2) PR: у50% reduction in the sum of perpendicular diameters of all measurable disease for a minimum of 30 days; (3) PR*: bone metastases in breast cancer required improvement in bone scans and plain films, demonstrating partial recalcification; and (4) progression of disease: Ͼ25% increase in measurable disease.
Cytotoxic assays
OVCAR and Daudi cells were obtained from the ATCC (Bethesda, MD, USA). OVCAR is an ovarian cancer cell line that expresses STn on the cell surface as determined by FACS analysis with the STn specific antibody B195. 31 Daudi cells do not express STn on their cell surface. The target cells were grown as previously outlined. 31 Cytotoxic assays were performed in triplicate for each vaccinated patient sample. Blood samples were obtained prior to each vaccination. Effector peripheral blood mononuclear cells (PBL) that had either been stimulated with or without IL-2 (Genzyme, Cambridge, MA, USA) (at a concentration of 10 6 cells/ml with 100 units/ml for 48-72 h) were then incubated with 51 Cr-labeled OVCAR or Daudi tumor targets as described previously 31 in a standard 51 Cr release assay. Cox regression models were fitted for the outcomes of survival and relapse. Both univariate and multivariable models were generated. The relative risk for the outcome of overall mortality represents the ratio of hazards of death for the appropriate groups, while the relative risk for the outcome of relapse represents the ratio of the hazards of relapse.
The correlation of the hazard of relapse with the specific lytic activity against STn + OVCAR cells relative to nonspecific killing of STn − Daudi cells was examined through Cox regression. For these purposes, the ratio of specific to nonspecific killing was treated as the explanatory variable of interest for the outcome of relapse. Patients who did not relapse were censored at time of death or last contact.
All reported P values were two-sided, and no adjustments were made for multiple comparisons. P values associated with regression models were derived from the Wald test.
Results

Toxicity of vaccination therapy
The most common toxicity reported in this study was local induration and erythema at the sites of injection (Table 2 ). No patients developed ulceration of the skin at the injection sites. The only premedication used in subsequent doses of vaccine was acetaminophen. Two patients, because of severe local site reaction, had Detox-B Stable Emulsion eliminated from subsequent doses of immunizations. One patient developed hypotension (blood pressure to 70/40) after the third immunization that did not require clinical intervention. She had no hypotension with subsequent immunizations. One patient withdrew from the study after the first immunization due to a previous job history of exposure to KLH and Detox-B Stable Emulsion. Two patients developed flu-like symptoms and withdrew themselves from the study, one after the first dose and the second after the fourth dose. Ten patients did not complete the total of five vaccinations due to disease progression: six patients received only two doses, two patients received three doses, and two patients received four doses. One patient required steroid therapy for another medical problem after the third immunization and received no further doses. In total, 26 patients (65%) received all five vaccine doses; 24 had breast cancer and two had ovarian cancer.
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Outcome
Patients in the control group had, on average, less advanced disease compared to vaccinated patients (Table 1) . For this reason, it was necessary to adjust analyses comparing outcome for this imbalance. After adjusting for the risk of relapse (low vs intermediate vs high), the hazards of death and relapse were suggestively higher among control patients compared to vaccinated patients (P = 0.07 and 0.10, respectively) (Tables 3 and 4, Figure 1 ). Since the majority of patients vaccinated were breast cancer patients, we also analyzed the data by restricting the group to breast cancer patients. The relative risk for mortality (hazard ratio: 2.14, 95% CI 0.82-5.59) (P = 0.12) and for relapse (hazard ratio: 1.69, 95% CI 0.84-3.43) (P = 0.14) remain basically the same as the whole group. Thus, the inclusion of ovarian cancer patients did not influence the association of treatment with outcome. In addition, adjustment for estrogen and progesterone receptor status had little impact on the relative hazards of death and relapse observed between the controls and vaccinated breast cancer patients (data not shown). Fourteen patients were in PR* (n = 10) or PR (n = 4) after transplant. Five PR* patients were documented as attaining a CR after initiation of vaccination. Every patient who died also had a prior relapse or progressive disease, and for this reason, the regression model for relapse is identical to the regression model for relapse-free survival.
Among the 26 vaccine patients alive at last contact, the median day of follow-up was 808 days after stem cell infusion, with a range of 536 to 1065 days. Among the 48 control patients alive at last contact, the median day of follow-up was 551 days after stem cell infusion, with a range of 151 to 1000 days.
Fourteen vaccine patients have died, and the median day to death among these patients was 335 days, with a range of 161 to 935 days. Among the 21 vaccine patients who relapsed, the median day to relapse was 279 days, with a range of 107 to 756 days. Among the 18 control patients who died, the median day to death was 399, with a range of 164 to 846 days. Among the 31 control patients who relapsed, the median day to relapse was 258 days, with a range of 2 to 999 days.
Correlation of immunological in vitro assays with clinical outcome
We were interested in determining whether the development of anti-STn tumor lytic activity correlated with clinical outcome. STn + OVCAR cells and STn − Daudi cells were used as 51 Cr-labeled targets to measure non-MHC restricted lytic activity in IL-2-treated PBLs from patients following immunotherapy. 31 We looked at the ratio of specific killing of the STn + OVCAR cells to nonspecific killing of STn − Daudi cells in Cox regression models that adjust for disease risk (low vs intermediate vs high) where the P value reported represents the significance of the ratio of OVCAR to Daudi killing (Table 5 ). If we use the transplant date as time zero, an increasing ratio of OVCAR to Daudi killing is associated with a decreasing hazard of relapse (P = 0.057). If the start of vaccination is used as time zero, P = 0.047. Similar correlation was not seen with the magnitude of antibody response to STn (data not shown).
Discussion
THERATOPE STn-KLH cancer vaccine was administered to 40 patients with breast or ovarian cancer following highdose chemotherapy followed by autologous or syngeneic PBSC rescue. Overall, the vaccine was well tolerated, with the most common toxicity being erythema and induration at the sites of injections ( Table 2) .
Since there are a number of different immunotherapy and chemotherapy agents available to study in combination with an autologous transplant, we retrospectively compared the outcome of the 40 vaccinated patients to 66 patients who were not vaccinated after transplant in order to gain preliminary evidence of potential efficacy of the vaccine. Patients in the control group, however, had on average less advanced disease compared to vaccinated patients (Table  1) . Thus, it was necessary to adjust analyses comparing outcome for this imbalance by taking into consideration the risk for relapse as defined, 'low', 'intermediate' or 'high'. When we controlled for the relative risk for relapse, the hazards of death (P = 0.07) and relapse (P = 0.10) in the control group tended to be higher than in the vaccinated group (Tables 3 and 4 , Figure 1 ). While the comparison is retrospective with non-randomized controls and the usual criteria for statistical significance (P Ͻ 0.05) are not reached, these data are promising enough to warrant further evaluation of the THERATOPE STn-KLH cancer vaccine and verification in a randomized phase III study.
The potential benefits that may be present for transplant patients who were vaccinated are similar to those reported for metastatic breast cancer patients treated in a nontransplant setting. Breast cancer patients pretreated with lowdose intravenous cyclophosphamide followed by THERA-TOPE STn-KLH cancer vaccine had longer survivals than those patients who received vaccine alone or low-dose oral cyclophosphamide followed by THERATOPE STn-KLH cancer vaccine, or a matched historical control group that did not receive THERATOPE vaccine. 15, 24, 25 Thus, in nontransplant patients, we have data to support a possible improvement in survival of patients treated with THERA-TOPE vaccine.
Laboratory parameters that measured the humoral and cell-mediated responses of these vaccinated stem cell transplant patients have been previously published. 31 Antigenspecific immunological recognition was documented. Transplant patients had a median anti-OSM IgG titer (a measure of anti-mucin STn) of 1:160 which compared favorably to the median titer of 1:40 in nontransplant metastatic breast and ovarian cancer patients who have been vaccinated with THERATOPE STn-KLH. 13, 14 An important observation was the development of anti-STn cellular immune responses in the transplant patients 31 which is the strongest evidence available of human T cell recognition of carbohydrate antigens. In the present report, it appears that the vaccinated patients with the greatest speBone Marrow Transplantation cific non-MHC restricted lytic activity against STn + OVCAR tumor cells, relative to nonspecific killing of STnDaudi cells, remained in remission longer than patients who displayed less specific immune activity (P = 0.057) ( Table  5 ). This observation is consistent with the hypothesis that the development of anti-STn non-MHC restricted lytic cells following vaccination with THERATOPE STn-KLH cancer vaccine correlates with clinical benefit to the transplant patients.
Patients who have received a transplant are more likely to have a relatively low tumor burden. As a result, transplant patients are less likely to have high levels of circulating MUC1 mucin which can cause T cell anergy. 29 Consequently, as they reconstitute immunologically, most stem cell transplant patients were able to respond to the THERA-TOPE STn-KLH cancer vaccine. 31 It should also be noted that the median day to initiation of vaccination for our group of patients was 127.5 days from stem cell infusion, and four patients did not reach their peak IgG anti-STn titer in response to the vaccine until after day 365.
After autologous transplantation, responses to protein recall antigens (ie poliovirus or tetanus toxoid) tend to recover faster than responses to neo-antigen proteins (ie KLH). Also, blood CD4
+ and CD8 + T cells are usually low until 3 months after stem cell transplant, and when they recover, are predominantly memory T cells. [33] [34] [35] Therefore, it is possible that many of the immunological responses seen in our vaccinated transplant patients may be due to reactivation by the vaccine of memory immune cells.
In future studies, there may be ways of increasing the immune reconstitution of patients following transplantation with immune stimulants like IL-2 or GM-CSF that, in combination with the THERATOPE STn-KLH cancer vaccine, may help to amplify the antigen-specific immune responses currently seen by giving THERATOPE STn-KLH alone. The potential for this approach in future studies is exemplified by the outcome of the three patients who received IL-2 therapy prior to vaccination (Ref. 31 and unpublished data) and the results of anti-STn tumor lytic activity demonstrated by IL-2-activated PBLS from vaccine patients (Table 5 ). In general, these patients displayed the earliest amplified antigen specific cellular immune responsiveness after initiation of vaccination. Whether such further amplification of specific immune responsiveness will translate into additional clinical benefits to the patients remains to be determined.
